{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:36:19Z","timestamp":1791005779351,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011790","name":"Xiangya Hospital, Central South University","doi-asserted-by":"publisher","award":["2016L06"],"award-info":[{"award-number":["2016L06"]}],"id":[{"id":"10.13039\/501100011790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["2021zzts1034"],"award-info":[{"award-number":["2021zzts1034"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ygyno.2022.06.015","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T03:02:51Z","timestamp":1656644571000},"page":"582-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis"],"prefix":"10.1016","volume":"166","author":[{"given":"Kun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.06.015_bb0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0010","first-page":"258","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0015","series-title":"SEER cancer statistics review 1975\u20132017","author":"Howlader","year":"2020"},{"key":"10.1016\/j.ygyno.2022.06.015_bb0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ygyno.2019.06.016","article-title":"Comprehensive genomic profiling of recurrent endometrial cancer: implications for selection of systemic therapy","volume":"154","author":"Prendergast","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0025","first-page":"2017","article-title":"Landscape of microsatellite instability across 39 cancer types","author":"Bonneville","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0030","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1158\/1078-0432.CCR-18-0412","article-title":"Clinical utility of prospective molecular characterization in advanced endometrial cancer","volume":"24","author":"Soumerai","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0035","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2022.06.015_bb0040","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1634\/theoncologist.2019-0407","article-title":"Clinical utility of prospective molecular characterization in advanced endometrial cancer","volume":"25","author":"Hao","year":"2020","journal-title":"The oncologist"},{"key":"10.1016\/j.ygyno.2022.06.015_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0050","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2019.12.039","article-title":"Second-line lenvatinib in patients with recurrent endometrial cancer","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0055","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0060","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0065","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.6004\/jnccn.2020.7796","article-title":"Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer","volume":"19","author":"Ding","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0070","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0075","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0080","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0085","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/13696998.2021.1917140","article-title":"Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer","volume":"24","author":"Thurgar","year":"2021","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11136-017-1704-4","article-title":"Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma","volume":"27","author":"de Groot","year":"2018","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0095","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1002\/cncr.32368","article-title":"First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a United States-based cost-effectiveness analysis","volume":"125","author":"Wan","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2022.06.015_bb0100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2021.05.038","article-title":"Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: a Markov analysis","volume":"162","author":"Ackroyd","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0105","author":"Centers for Medicare & Medicaid Services"},{"key":"10.1016\/j.ygyno.2022.06.015_bb0110","author":"Drugs.com"},{"key":"10.1016\/j.ygyno.2022.06.015_bb0115","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ygyno.2021.06.014","article-title":"Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis","volume":"162","author":"Barrington","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2021.12.007","article-title":"Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer","volume":"164","author":"Shi","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0440-9","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma","volume":"6","author":"Wu","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2022.06.015_bb0130","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1002\/ONCO.13522","article-title":"Cost-effectiveness of pembrolizumab plus axitinib versus sunitinib as first-line therapy in advanced renal cell carcinoma in the U.S","volume":"26","author":"Ding","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2022.06.015_bb0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3111\/13696998.2014.985789","article-title":"Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US","volume":"18","author":"Perrin","year":"2015","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lungcan.2010.10.017","article-title":"Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer","volume":"73","author":"Zietemann","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ygyno.2022.06.015_bb0145","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1097\/JTO.0b013e3181bbf223","article-title":"Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice","volume":"4","author":"Girard","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-5002(02)00308-2","article-title":"A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer","volume":"39","author":"Massarelli","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ygyno.2022.06.015_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061478","article-title":"The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions","volume":"13","author":"Alexa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2022.06.015_bb0160","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0165","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.06.015_bb0170","first-page":"1","article-title":"A review of immune checkpoint blockade therapy in endometrial cancer","volume":"40","author":"Green","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582200419X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582200419X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:01:57Z","timestamp":1758772917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582200419X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S009082582200419X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.06.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}